Alumis Inc. (ALMS)
$6.06-7.62%Close
SELLCRISIS · day 46
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $748M
- Beta
- -0.67
- P/E (TTM)
- -1.59
- Short % float
- 11.99%
- Days to cover
- 3.6
- SI change
- +63.5%
- 1W
- -10.49%
- 1M
- -27.86%
- vs SPY 1W
- -10.35%
- vs SPY 1M
- -30.36%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ALMS?
- LOPJLB’s latest quantitative signal on Alumis Inc. (ALMS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ALMS in?
- Alumis Inc. (ALMS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Alumis Inc. (ALMS) do?
- Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment…